Mobile

A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes Mellitus and End-Stage Renal Disease Who Are on Dialy...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-003529-26

A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes Mellitus and End-Stage Renal Disease Who Are on Dialysis and Who Have Inadequate Glycemic Control

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

After 54 weeks, to assess the effect (change from baseline) of sitagliptin on HbA1c; After 54 weeks, to assess the safety and tolerability of sitagliptin.

Critère d'inclusion

  • type II diabetes mellitus

Liens